房颤合并支架植入患者不同抗栓方案的有效性与安全性比较
本研究利用台湾全民健康保险研究资料库与死亡登记库,回顾性纳入2007-2017年首次接受冠脉支架植入的非瓣膜性房颤患者10208例,比较不同抗栓方案的主要不良心血管事件(MACE)与大出血风险。出院时68.4%患者处方双联抗血小板治疗(DAPT);随访中双联治疗(抗血小板+抗凝)最常用。双联治疗与DAPT的MACE风险相当(aHR 0.86,95%CI 0.67-1.11);三联治疗与双联或DAPT有效性相似,但大出血风险近乎翻倍。
要点
- 亚洲房颤合并支架患者出院时最常用DAPT(68.4%)。
- 双联治疗与DAPT的MACE风险相当(aHR 0.86,95%CI 0.67-1.11)。
- 三联治疗大出血风险显著高于DAPT和双联治疗。
核心结论
- 在亚洲房颤合并支架植入患者中,DAPT、双联治疗与三联治疗的MACE风险相当,但三联治疗的大出血风险显著高于DAPT或双联治疗。
研究设计与样本
- 回顾性队列研究,使用台湾全民健康保险研究资料库与死亡登记库,纳入2007-2017年首次接受经皮冠状动脉介入并植入支架的非瓣膜性房颤患者10208例。
主要发现
- 出院时68.4%患者处方DAPT;随访期间抗凝药使用增加,双联治疗(抗血小板+抗凝)最为常用。
- 双联治疗与DAPT的MACE风险相当(aHR 0.86,95%CI 0.67-1.11)。
- 三联治疗与双联治疗(aHR 1.23,95%CI 0.84-1.80)或DAPT(aHR 1.06,95%CI 0.77-1.45)的MACE风险相似。
- 三联治疗的大出血风险近乎为DAPT的2倍(aHR 1.97,95%CI 1.31-2.94),也高于双联治疗(aHR 1.80,95%CI 1.10-2.95)。
临床怎么用
- 对于亚洲房颤合并支架植入患者,选择抗栓方案时需权衡缺血与出血风险,三联治疗虽有效性不劣但大出血风险显著增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aims to compare the risks of major adverse cardiac events (MACEs), including cardiovascular death, myocardial infarction, ischemic stroke and transient ischemic attack, and major bleeding across different antithrombotic regimens in Asian patients with atrial fibrillation (AF) with stent insertions. We conducted a retrospective cohort study using Taiwan's National Health Insurance Research Database and National Mortality Registry. A total of 10,208 patients with nonvalvular AF who had undergone percutaneous coronary intervention with stents for the first time in 2007-2017 were identified. Most patients (68.4%) were prescribed dual antiplatelet therapy (DAPT) at discharge. During follow-up, the use of anticoagulants increased, and double therapy (an antiplatelet plus an anticoagulant) was the most frequently prescribed therapy. The risks of MACEs were comparable in double therapy and had a similar risk of MACEs compared with DAPT (adjusted hazard ratio (aHR) 0.86, 95% confidence interval (CI) 0.67-1.11). Triple therapy (DAPT plus an anticoagulant) also had similar effectiveness to double therapy (aHR 1.23, 95% CI 0.84-1.80) or DAPT (aHR 1.06, 95% CI 0.77-1.45). However, triple therapy was associated with a nearly twofold higher major bleeding risk than DAPT and double therapy (aHR 1.97, 95% CI 1.31-2.94 and aHR 1.80, 95% CI 1.10-2.95, respectively). DAPT was the most frequently prescribed antithrombotic regimen at discharge for Asian patients with AF who had undergone stent insertions. DAPT and double and triple therapy had comparable effectiveness, but triple therapy had a significantly higher major bleeding risk than either DAPT or double therapy.
引用
- Chueh HH, Huang ST, Chang SH, et al. Comparative Effectiveness and Safety of Different Combinations of Antithrombotic Regimens in Atrial Fibrillation Patients With Stent Insertions. Clin Pharmacol Ther. 2022. PMID: 35680555. doi:10.1002/cpt.2684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。